Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06097676 · ClinicalTrials.gov registry record · Phase 4
An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users
A Phase 4 study, sponsored by Arbor Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 86
- Enrollment target
NCT06097676 is a Phase 4 study that has completed, run by Arbor Pharmaceuticals. The registered enrollment target is 86 participants.
The verdict
NCT06097676, a Phase 4 study, has completed, sponsored by Arbor Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the abuse potential of gabapentin enacarbil in healthy adult, non-dependent, recreational drug users.
Interventions
- DRUG Placebo
- DRUG Alprazolam 2 mg
- DRUG Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg
- DRUG Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg
- DRUG Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2021-09-28 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06097676
The ClinicalTrials.gov registry entry for NCT06097676 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arbor Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT06097676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06097676 about?
NCT06097676 is a clinical study titled "An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users". The purpose of this study is to assess the abuse potential of gabapentin enacarbil in healthy adult, non-dependent, recreational drug users.
What is the current status of trial NCT06097676?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 2021-09-28. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT06097676?
The interventions under investigation include: Placebo (DRUG), Alprazolam 2 mg (DRUG), Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg (DRUG), Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg (DRUG), Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg (DRUG).
Who is sponsoring clinical trial NCT06097676?
This trial is sponsored by Arbor Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.